Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Abstract Text:

Kuei C Lee,Bradford A Moffat,Anne F Schott,Rachel Layman,Steven Ellingworth,Rebecca Juliar,Amjad P Khan,Mark Helvie,Charles R Meyer,Thomas L Chenevert,Alnawaz Rehemtulla,Brian D Ross,

PURPOSE: The American Cancer Society estimates that in 2006, 212,920 women will be diagnosed with breast cancer and that 40,970 women will die from the disease. The development of more efficacious chemotherapies has improved outcomes, but the rapid assessment of clinical benefit from these agents remains challenging. In breast cancer patients receiving neoadjuvant chemotherapy, treatment response is traditionally assessed by physical examination and volumetric-based measurements, which are subjective and require macroscopic changes in tumor morphology. In this study, we evaluate the feasibility of using diffusion magnetic resonance imaging (MRI) as a reliable and quantitative measure for the early assessment of response in a breast cancer model. EXPERIMENTAL DESIGN: Mice implanted with human breast cancer (MX-1) were treated with cyclophosphamide and evaluated using diffusion MRI and growth kinetics. Histologic analyses using terminal nucleotidyl transferase-mediated nick end labeling and H&E were done on tumor samples for correlation with imaging results. RESULTS: Cyclophosphamide treatment resulted in a significant reduction in tumor volumes compared with controls. The mean apparent diffusion change for treated tumors at days 4 and 7 posttreatment was 44 +/- 5% and 94 +/- 7%, respectively, which was statistically greater (P < 0.05) than the control tumors at the same time intervals. The median time-to-progression for control and treated groups was 11 and 32 days, respectively (P < 0.05). CONCLUSION: Diffusion MRI was shown to detect early changes in the tumor microenvironment, which correlated with standard measures of tumor response as well as overall outcome. Moreover, these findings show the feasibility of using diffusion MRI for assessing treatment response of a breast tumor model in a neoadjuvant setting.

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Publishing Authors By Initials

KC Lee,BA Moffat,AF Schott,R Layman,S Ellingworth,R Juliar,AP Khan,M Helvie,CR Meyer,TL Chenevert,A Rehemtulla,BD Ross,

For similar biological factors: biological markers: tumor markers, biological research abstracts see: biological factors: biological markers: tumor markers, biological research

PUBMED ID PMID:

MEDLINE DATE:

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 443-50

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 15

MONTH: Jan

YEAR: 2007

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Keywords Mesh Terms:

KEYWORDS: Tumor Markers, Biological

MESH TERMS: therapy

Chemical & Substance for Abstract: Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Information

Substance Name: Cyclophosphamide

Registry Number: 50-18-0

Grant and Affiliation Information for Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.

AFFILIATION: Department of Radiology, Center for Molecular Imaging, University of Michigan Medical School, Biomedical Sciences Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA.

Country: United States

AGENCY: United States NCI

GRANT: R24 CA 83099

ACRONYM: CA

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy Related Publications

• A minimum CR2 binding domain of C3d enhances immunity following vaccination.
• Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children.
• Benjamin M. Baker, JR.: 1901-2003.
• Birth characteristics, maternal reproductive history, and the risk of infant leukemia: a report from the Children's Oncology Group.
• Carnitine as a possible adjunct in parenteral feeding.
• Chronic vitamin A status and acute repletion with retinyl palmitate are determinants of the distribution and catabolism of all-trans-retinoic acid in rats.
• Circadian rhythms play role in cancer research.
• Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri.
• Differences in cyclin D2 and D1 protein expression distinguish forebrain progenitor subsets.
• Diffusion imaging: insight to cell status and cytoarchitecture.
• Failure of embryos from bluetongue infected cattle to transmit virus to susceptible recipients or their offspring.
• Gestational programming of offspring obesity/hypertension.
• Kinetics of glial glutamine efflux and the mechanism of neuronal uptake studied in vivo in mildly hyperammonemic rat brain.
• Language use in females with fragile X or Turner syndrome during brief initial social interactions.
• Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.
• Maternal hemoglobin concentration during pregnancy and risk of infant leukaemia: a children's oncology group study.
• More to the E-Ferol case than presented.
• Neurologic Manifestations
  of HIV Infection Without AIDS:Follow-UP of a Cohort
  of Homosexual and Bisexual Men.
• Penicillin; applied pharmacology.
• Phosphorylation-regulated inhibition of the Gz GTPase-activating protein activity of RGS proteins by synapsin I.
• Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.
• Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
• Random activation energy model and disordered kinetics, from static to dynamic disorder.
• Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope.
• Species differences in the in vitro metabolism of deltamethrin and esfenvalerate: differential oxidative and hydrolytic metabolism by humans and rats.
• The effect of lactation length on the circulating concentrations of progesterone and oestradiol in the early weaned sow.
• Transoral surgery: an anatomic study.
• Use of modified pericranial flaps in anterior skull base reconstruction: technical note.
• Vascular targeted nanoparticles for imaging and treatment of brain tumors.
• Virus-like particles: designing an effective AIDS vaccine.